A U.S. federal judge rejected Swiss drugmaker Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from ...

Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...

The District Court for the District of Delaware recently rejected Novartis’s effort to block MSN Pharmaceuticals from launching a generic version ...

Swiss pharmaceutical giant Novartis has raised its full-year earnings forecast, citing robust revenue growth from key ...

Novartis could soon face generic competition for Entresto after judge's ruling.

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...

Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction ...